Form 8-K Oruka Therapeutics, Inc. For: May 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Oruka Therapeutics expands license agreement to include IBD indication
June 1, 2026 4:05 PM EDTOruka Therapeutics Inc. (NASDAQ: ORKA) amended its IL-23 license agreement with Paragon Therapeutics Inc. on May 29, 2026, expanding the therapeutic field to include inflammatory bowel disease.
The amendment modifies the original license agreement dated December 17, 2024, broadening the definition of "Field" to encompass all therapeutic,... More
